Pfizer aims to make 10 million to 20 million doses of a coronavirus vaccine it is developing with BioNTech by the end of 2020 for emergency use depending on trial results, as reported in London South East.
Nanette Cocero, global head of Pfizer Vaccines, said "we need to see and wait to see how the vaccine's efficacy and safety is demonstrated, hopefully in the coming months."
However, she said that "assuming that is demonstrated, we are looking to ramp up manufacturing rather quickly to have around 10 million to 20 million doses by the end of this year, which are expected to then…be used in an emergency type of setting."
The companies, which are developing four vaccine candidates, have already dosed the first humans in Germany and hope to begin a US trial soon, pending approval by regulators.
To read more NewsPoints articles, click here.